These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24450340)

  • 21. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
    Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
    Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
    Özgür A; Tutar Y
    Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
    Bickel D; Gohlke H
    Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
    Li J; Soroka J; Buchner J
    Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.
    Serwetnyk MA; Blagg BSJ
    Acta Pharm Sin B; 2021 Jun; 11(6):1446-1468. PubMed ID: 34221862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
    Koay YC; Wahyudi H; McAlpine SR
    Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90 & Co. - a holding for folding.
    Buchner J
    Trends Biochem Sci; 1999 Apr; 24(4):136-41. PubMed ID: 10322418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat shock protein 90 from Escherichia coli collaborates with the DnaK chaperone system in client protein remodeling.
    Genest O; Hoskins JR; Camberg JL; Doyle SM; Wickner S
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8206-11. PubMed ID: 21525416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
    Mishra SJ; Liu W; Beebe K; Banerjee M; Kent CN; Munthali V; Koren J; Taylor JA; Neckers LM; Holzbeierlein J; Blagg BSJ
    J Med Chem; 2021 Feb; 64(3):1545-1557. PubMed ID: 33428418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.
    Wang Y; McAlpine SR
    Org Biomol Chem; 2015 Apr; 13(16):4627-31. PubMed ID: 25711919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting HSP90 for cancer therapy.
    Mahalingam D; Swords R; Carew JS; Nawrocki ST; Bhalla K; Giles FJ
    Br J Cancer; 2009 May; 100(10):1523-9. PubMed ID: 19401686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
    Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
    Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.
    Pratt WB; Toft DO
    Exp Biol Med (Maywood); 2003 Feb; 228(2):111-33. PubMed ID: 12563018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HSP90 chaperone machinery.
    Schopf FH; Biebl MM; Buchner J
    Nat Rev Mol Cell Biol; 2017 Jun; 18(6):345-360. PubMed ID: 28429788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp90 chaperones wild-type p53 tumor suppressor protein.
    Walerych D; Kudla G; Gutkowska M; Wawrzynow B; Muller L; King FW; Helwak A; Boros J; Zylicz A; Zylicz M
    J Biol Chem; 2004 Nov; 279(47):48836-45. PubMed ID: 15358769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines.
    Pimienta G; Herbert KM; Regan L
    Mol Pharm; 2011 Dec; 8(6):2252-61. PubMed ID: 21882818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
    Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.